Zinger Key Points
- Avantor reported Q4 net sales of $1.69 billion, down 2% YoY, missing estimates. Adjusted EPS was $0.27, beating the consensus of $0.26.
- Net income surged to $500.4 million. The company forecasts 2025 organic revenue growth of 1%-3%.
- Brand New Membership Level: Benzinga Trade Alerts
On Friday, Avantor Inc AVTR reported fourth-quarter net sales of $1.69 billion, a decrease of 2% year-over-year, missing the consensus of $1.71 billion.
Foreign currency translation and Clinical Services divestiture had a negative impact, resulting in sales growth of 1% on an organic basis.
Net income increased to $500.4 million from $98.5 million a year ago, and adjusted net income was $183.9 million compared to $166.7 million in the comparable prior period.
Also Read: Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis
The life science tools company reported the adjusted EBITDA was $307.7 million, and the margin was 18.2%. Adjusted operating income was $279.4, with a margin of 16.6%.
The company reported an adjusted EPS of 27 cents, up from 29 cents a year ago, beating the consensus of 26 cents.
Operating cash flow was $173.3 million, while free cash flow was $222.1 million.
“As anticipated, we returned to growth in the fourth quarter and delivered sequential and year-over-year growth in adjusted EBITDA margin, adjusted EPS, and best-in-class free cash flow conversion. We grew our bioprocessing platform high-single-digits and expect continued strength driven by our focused execution and improving end market conditions,” said Michael Stubblefield, President and Chief Executive Officer.
Laboratory Solutions’ net sales were $1.13 billion, down 5%. Foreign currency translation and our Clinical Services divestiture had a negative impact, resulting in a 1% organic sales decline.
Bioscience Production net sales were $560.8 million, up 4%. Sales increased 4% organically.
Guidance: Avantor expects 2025 organic revenue growth of 1%-3% compared to 2024 decline of 2%, with adjusted EBITDA margin of 18%-19%
The company forecasts adjusted EPS of $1.02-$1.10 versus the consensus of $1.10 and expected free cash flow of $650 million—$700 million.
Price Action: AVTR stock is down 3.73% at $20.89 during the premarket session on last check Friday.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
